| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 186 | 2025 | 3250 | 10.320 |
Why?
|
| T-Lymphocytes, Regulatory | 44 | 2024 | 3115 | 5.240 |
Why?
|
| Autoimmunity | 34 | 2024 | 1361 | 4.460 |
Why?
|
| T-Lymphocytes | 127 | 2022 | 10266 | 3.830 |
Why?
|
| Autoimmune Diseases | 46 | 2024 | 2257 | 3.520 |
Why?
|
| CD4-Positive T-Lymphocytes | 47 | 2025 | 4415 | 3.110 |
Why?
|
| Forkhead Transcription Factors | 22 | 2024 | 1625 | 3.080 |
Why?
|
| T-Lymphocyte Subsets | 41 | 2023 | 1816 | 2.970 |
Why?
|
| Autoantigens | 35 | 2019 | 890 | 2.680 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 15 | 2020 | 558 | 2.480 |
Why?
|
| Lymphocyte Activation | 86 | 2022 | 5505 | 2.440 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 28 | 2016 | 897 | 2.280 |
Why?
|
| Central Nervous System | 16 | 2022 | 1346 | 2.260 |
Why?
|
| Th17 Cells | 10 | 2018 | 791 | 2.130 |
Why?
|
| HLA-DR Antigens | 25 | 2012 | 609 | 2.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 25 | 2024 | 4648 | 1.820 |
Why?
|
| B-Lymphocytes | 26 | 2025 | 4793 | 1.810 |
Why?
|
| Receptors, Interleukin-2 | 17 | 2006 | 564 | 1.740 |
Why?
|
| Th1 Cells | 13 | 2018 | 1042 | 1.730 |
Why?
|
| Clone Cells | 57 | 2021 | 1670 | 1.660 |
Why?
|
| Interleukin-17 | 9 | 2022 | 924 | 1.640 |
Why?
|
| Immune Tolerance | 29 | 2021 | 2323 | 1.510 |
Why?
|
| Interferon-gamma | 32 | 2024 | 3161 | 1.490 |
Why?
|
| Neuroimmunomodulation | 4 | 2022 | 187 | 1.450 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 16 | 2023 | 977 | 1.400 |
Why?
|
| Antigens, CD | 33 | 2016 | 4035 | 1.400 |
Why?
|
| Receptors, Virus | 6 | 2013 | 651 | 1.360 |
Why?
|
| Cytokines | 44 | 2023 | 7452 | 1.350 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 6 | 2011 | 306 | 1.290 |
Why?
|
| Genetic Predisposition to Disease | 49 | 2024 | 18065 | 1.240 |
Why?
|
| Histocompatibility Antigens Class II | 14 | 2021 | 1441 | 1.230 |
Why?
|
| Human T-lymphotropic virus 1 | 14 | 2001 | 143 | 1.180 |
Why?
|
| Receptors, Antigen, T-Cell | 43 | 2022 | 2568 | 1.150 |
Why?
|
| Receptors, Immunologic | 14 | 2022 | 1418 | 1.090 |
Why?
|
| Antigens, Differentiation | 15 | 2007 | 921 | 1.090 |
Why?
|
| Interleukin-4 | 23 | 2006 | 1156 | 1.080 |
Why?
|
| Immediate-Early Proteins | 4 | 2024 | 444 | 1.080 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 20 | 2021 | 812 | 1.070 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 18 | 2014 | 822 | 1.020 |
Why?
|
| Sodium Chloride | 3 | 2021 | 584 | 1.020 |
Why?
|
| Antigen Presentation | 14 | 2012 | 1251 | 0.970 |
Why?
|
| Receptors, KIR | 1 | 2024 | 114 | 0.930 |
Why?
|
| Single-Cell Analysis | 9 | 2024 | 2540 | 0.930 |
Why?
|
| Self Tolerance | 4 | 2017 | 122 | 0.920 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2025 | 173 | 0.920 |
Why?
|
| Humans | 422 | 2025 | 768171 | 0.910 |
Why?
|
| Interleukin-10 | 16 | 2018 | 1184 | 0.900 |
Why?
|
| Sodium Chloride, Dietary | 3 | 2016 | 301 | 0.890 |
Why?
|
| Inflammation | 20 | 2023 | 10873 | 0.880 |
Why?
|
| Alleles | 26 | 2024 | 6894 | 0.860 |
Why?
|
| Major Histocompatibility Complex | 17 | 2013 | 877 | 0.810 |
Why?
|
| Myelin-Associated Glycoprotein | 7 | 2011 | 110 | 0.790 |
Why?
|
| Immunologic Factors | 7 | 2018 | 1596 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 1 | 14 | 2013 | 3447 | 0.790 |
Why?
|
| Status Epilepticus | 2 | 2024 | 463 | 0.760 |
Why?
|
| Myelin Proteins | 15 | 2013 | 212 | 0.760 |
Why?
|
| Tumor Escape | 3 | 2024 | 372 | 0.750 |
Why?
|
| Membrane Glycoproteins | 16 | 2017 | 3713 | 0.740 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2021 | 1801 | 0.740 |
Why?
|
| Epitopes, T-Lymphocyte | 9 | 2011 | 827 | 0.740 |
Why?
|
| Polymorphism, Single Nucleotide | 41 | 2024 | 16044 | 0.720 |
Why?
|
| Flow Cytometry | 24 | 2023 | 5902 | 0.720 |
Why?
|
| Oleic Acid | 1 | 2021 | 91 | 0.720 |
Why?
|
| Autoantibodies | 17 | 2021 | 2121 | 0.700 |
Why?
|
| Immunoconjugates | 10 | 2008 | 975 | 0.700 |
Why?
|
| Interleukin-2 | 25 | 2017 | 1895 | 0.700 |
Why?
|
| Benzyl Compounds | 1 | 2019 | 19 | 0.690 |
Why?
|
| Cell Differentiation | 16 | 2024 | 11677 | 0.680 |
Why?
|
| Transforming Growth Factor beta1 | 4 | 2016 | 642 | 0.670 |
Why?
|
| Cells, Cultured | 39 | 2022 | 19025 | 0.650 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 3 | 2018 | 48 | 0.650 |
Why?
|
| Myelin Sheath | 9 | 2015 | 652 | 0.640 |
Why?
|
| RNA, Messenger | 17 | 2024 | 12801 | 0.630 |
Why?
|
| Gene Expression Regulation | 19 | 2022 | 11930 | 0.610 |
Why?
|
| Azetidines | 1 | 2019 | 152 | 0.610 |
Why?
|
| Animals | 98 | 2025 | 169285 | 0.600 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 3 | 2014 | 151 | 0.600 |
Why?
|
| HLA-A2 Antigen | 5 | 2003 | 207 | 0.600 |
Why?
|
| Interferon Type I | 2 | 2022 | 569 | 0.600 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 4 | 2009 | 318 | 0.600 |
Why?
|
| Peptides | 14 | 2012 | 4354 | 0.590 |
Why?
|
| Gene Products, tax | 6 | 2003 | 51 | 0.590 |
Why?
|
| Immunotherapy | 18 | 2021 | 4754 | 0.580 |
Why?
|
| Genetics, Population | 3 | 2022 | 944 | 0.580 |
Why?
|
| Membrane Proteins | 13 | 2014 | 7876 | 0.580 |
Why?
|
| Antibodies, Monoclonal | 35 | 2023 | 9262 | 0.560 |
Why?
|
| Gene Expression Profiling | 17 | 2024 | 9540 | 0.560 |
Why?
|
| Th2 Cells | 8 | 2013 | 1078 | 0.560 |
Why?
|
| Peptide Fragments | 19 | 2014 | 5151 | 0.550 |
Why?
|
| Immunophenotyping | 13 | 2021 | 1864 | 0.540 |
Why?
|
| Borrelia burgdorferi Group | 4 | 2001 | 96 | 0.540 |
Why?
|
| Chromosome Mapping | 12 | 2024 | 4620 | 0.530 |
Why?
|
| Immunologic Memory | 11 | 2010 | 1377 | 0.520 |
Why?
|
| Signal Transduction | 34 | 2016 | 23648 | 0.520 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1105 | 0.520 |
Why?
|
| Antigens, Surface | 13 | 2005 | 1617 | 0.520 |
Why?
|
| Melanoma | 3 | 2024 | 5706 | 0.510 |
Why?
|
| Models, Immunological | 8 | 2016 | 518 | 0.510 |
Why?
|
| Cytotoxicity, Immunologic | 10 | 2021 | 1353 | 0.510 |
Why?
|
| Paraparesis, Tropical Spastic | 6 | 1999 | 32 | 0.500 |
Why?
|
| Clonal Deletion | 1 | 2015 | 75 | 0.490 |
Why?
|
| Cholesterol | 1 | 2024 | 2914 | 0.490 |
Why?
|
| Glutarates | 1 | 2017 | 242 | 0.490 |
Why?
|
| Demyelinating Diseases | 8 | 2022 | 358 | 0.490 |
Why?
|
| Immune System | 4 | 2018 | 800 | 0.490 |
Why?
|
| Immunosuppressive Agents | 12 | 2015 | 4206 | 0.490 |
Why?
|
| HTLV-I Infections | 7 | 2001 | 104 | 0.480 |
Why?
|
| Clonal Anergy | 4 | 2014 | 169 | 0.480 |
Why?
|
| Microglia | 8 | 2024 | 1376 | 0.460 |
Why?
|
| Genome-Wide Association Study | 28 | 2024 | 12795 | 0.460 |
Why?
|
| Phenotype | 27 | 2024 | 16726 | 0.460 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2014 | 169 | 0.460 |
Why?
|
| Molecular Sequence Data | 42 | 2013 | 17623 | 0.450 |
Why?
|
| Lyme Disease | 6 | 2021 | 630 | 0.450 |
Why?
|
| Neurogenic Inflammation | 1 | 2014 | 34 | 0.450 |
Why?
|
| Epitopes | 17 | 2023 | 2527 | 0.450 |
Why?
|
| Inflammation Mediators | 5 | 2016 | 1892 | 0.440 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2019 | 3781 | 0.430 |
Why?
|
| Cell Line, Transformed | 11 | 2012 | 866 | 0.430 |
Why?
|
| beta Catenin | 1 | 2018 | 1047 | 0.430 |
Why?
|
| Coculture Techniques | 8 | 2015 | 1344 | 0.430 |
Why?
|
| Mice | 48 | 2025 | 82049 | 0.420 |
Why?
|
| Cell Separation | 9 | 2018 | 1728 | 0.410 |
Why?
|
| Monocytes | 6 | 2016 | 2605 | 0.410 |
Why?
|
| Meninges | 2 | 2012 | 197 | 0.410 |
Why?
|
| Immunodominant Epitopes | 5 | 2000 | 244 | 0.400 |
Why?
|
| Macrophage Activation | 1 | 2015 | 557 | 0.400 |
Why?
|
| Interleukin-12 | 7 | 2011 | 577 | 0.400 |
Why?
|
| Transforming Growth Factor beta | 8 | 2009 | 2004 | 0.400 |
Why?
|
| Amino Acid Sequence | 33 | 2013 | 13422 | 0.400 |
Why?
|
| Myelin Proteolipid Protein | 9 | 1998 | 107 | 0.390 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2023 | 1854 | 0.390 |
Why?
|
| Environment | 3 | 2019 | 1121 | 0.390 |
Why?
|
| Cerebrospinal Fluid | 10 | 2018 | 540 | 0.390 |
Why?
|
| Propylene Glycols | 1 | 2012 | 91 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 3670 | 0.380 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2011 | 19 | 0.380 |
Why?
|
| Glioblastoma | 5 | 2020 | 3464 | 0.370 |
Why?
|
| HLA Antigens | 6 | 2010 | 1334 | 0.370 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2011 | 82 | 0.360 |
Why?
|
| RNA, Small Interfering | 6 | 2017 | 3428 | 0.350 |
Why?
|
| Immunity | 3 | 2016 | 1003 | 0.340 |
Why?
|
| Interleukin-9 | 1 | 2010 | 62 | 0.340 |
Why?
|
| Antigens | 9 | 2014 | 1443 | 0.340 |
Why?
|
| Case-Control Studies | 25 | 2024 | 22290 | 0.340 |
Why?
|
| Adult | 91 | 2025 | 223646 | 0.340 |
Why?
|
| Brain | 18 | 2024 | 27362 | 0.340 |
Why?
|
| Genetic Variation | 14 | 2013 | 6610 | 0.340 |
Why?
|
| Antibody Formation | 5 | 2023 | 1393 | 0.340 |
Why?
|
| Sphingosine | 1 | 2012 | 308 | 0.330 |
Why?
|
| Lipoproteins | 3 | 2005 | 880 | 0.330 |
Why?
|
| Dendritic Cells | 5 | 2014 | 2747 | 0.330 |
Why?
|
| Down-Regulation | 5 | 2014 | 2939 | 0.320 |
Why?
|
| Haplotypes | 13 | 2020 | 2722 | 0.320 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 3833 | 0.320 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2015 | 257 | 0.320 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 3 | 2013 | 68 | 0.320 |
Why?
|
| Databases, Genetic | 2 | 2015 | 1758 | 0.310 |
Why?
|
| Antigen-Presenting Cells | 12 | 2008 | 960 | 0.310 |
Why?
|
| Immunomagnetic Separation | 2 | 2006 | 78 | 0.310 |
Why?
|
| Cross Reactions | 9 | 2004 | 828 | 0.310 |
Why?
|
| Cathepsins | 1 | 2009 | 243 | 0.300 |
Why?
|
| Ligands | 9 | 2022 | 3284 | 0.300 |
Why?
|
| B-Lymphocyte Subsets | 5 | 2012 | 241 | 0.300 |
Why?
|
| Interleukins | 3 | 2014 | 796 | 0.300 |
Why?
|
| Lymph Nodes | 5 | 2014 | 3474 | 0.290 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 8052 | 0.290 |
Why?
|
| Genotype | 22 | 2016 | 13045 | 0.290 |
Why?
|
| Female | 108 | 2025 | 397187 | 0.290 |
Why?
|
| NF-kappa B | 2 | 2015 | 2494 | 0.280 |
Why?
|
| Male | 98 | 2025 | 364731 | 0.280 |
Why?
|
| Gene Silencing | 5 | 2019 | 1505 | 0.280 |
Why?
|
| Bacterial Outer Membrane Proteins | 3 | 2005 | 404 | 0.280 |
Why?
|
| HLA-A Antigens | 4 | 2011 | 223 | 0.270 |
Why?
|
| Sodium | 2 | 2023 | 1597 | 0.270 |
Why?
|
| Interferon-beta | 7 | 2014 | 349 | 0.270 |
Why?
|
| Dose-Response Relationship, Immunologic | 6 | 2002 | 361 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 11 | 2016 | 3814 | 0.260 |
Why?
|
| Immunoglobulin G | 8 | 2023 | 4568 | 0.260 |
Why?
|
| Cell Communication | 5 | 2013 | 1660 | 0.260 |
Why?
|
| Copyright | 1 | 2005 | 13 | 0.260 |
Why?
|
| Genetic Heterogeneity | 2 | 2009 | 736 | 0.260 |
Why?
|
| Gene Frequency | 12 | 2019 | 3623 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 4 | 2014 | 874 | 0.250 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 3 | 2011 | 50 | 0.250 |
Why?
|
| Cell Line | 24 | 2010 | 15602 | 0.250 |
Why?
|
| Cell Division | 12 | 2004 | 4477 | 0.250 |
Why?
|
| Middle Aged | 68 | 2025 | 223487 | 0.250 |
Why?
|
| Immunity, Innate | 9 | 2022 | 3080 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 5863 | 0.240 |
Why?
|
| Cell Proliferation | 10 | 2024 | 10478 | 0.240 |
Why?
|
| Medical Illustration | 1 | 2005 | 135 | 0.240 |
Why?
|
| Molecular Mimicry | 3 | 2001 | 213 | 0.240 |
Why?
|
| Antibodies | 9 | 2014 | 2421 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2009 | 640 | 0.230 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2006 | 256 | 0.230 |
Why?
|
| Pancreatic Elastase | 1 | 2024 | 125 | 0.230 |
Why?
|
| Glioma | 2 | 2017 | 3503 | 0.230 |
Why?
|
| Quantitative Trait Loci | 6 | 2024 | 2131 | 0.230 |
Why?
|
| Lectins, C-Type | 3 | 2017 | 594 | 0.220 |
Why?
|
| Killer Cells, Natural | 6 | 2021 | 2211 | 0.220 |
Why?
|
| Complementarity Determining Regions | 2 | 2001 | 154 | 0.220 |
Why?
|
| Toll-Like Receptors | 4 | 2014 | 582 | 0.220 |
Why?
|
| Antibodies, Heterophile | 2 | 2001 | 128 | 0.220 |
Why?
|
| Systems Biology | 3 | 2016 | 482 | 0.220 |
Why?
|
| Macrophages | 5 | 2015 | 5802 | 0.220 |
Why?
|
| CD40 Ligand | 3 | 2022 | 528 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2025 | 1049 | 0.220 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 958 | 0.220 |
Why?
|
| Lymphotoxin-alpha | 1 | 2003 | 94 | 0.210 |
Why?
|
| Transcription Factor AP-1 | 1 | 2024 | 321 | 0.210 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 5 | 1997 | 111 | 0.210 |
Why?
|
| Interleukin-5 | 4 | 2000 | 267 | 0.210 |
Why?
|
| HLA-DR2 Antigen | 4 | 1995 | 45 | 0.200 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2024 | 110 | 0.200 |
Why?
|
| Lymphocytes | 6 | 2014 | 2614 | 0.200 |
Why?
|
| Transcription, Genetic | 10 | 2024 | 7609 | 0.200 |
Why?
|
| Gene Expression | 8 | 2021 | 7601 | 0.200 |
Why?
|
| Disease Susceptibility | 5 | 2014 | 1793 | 0.200 |
Why?
|
| Antibody Affinity | 1 | 2003 | 252 | 0.200 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2016 | 2596 | 0.200 |
Why?
|
| Body Fluids | 1 | 2024 | 321 | 0.200 |
Why?
|
| GATA3 Transcription Factor | 2 | 2013 | 163 | 0.200 |
Why?
|
| Protein Binding | 9 | 2014 | 9343 | 0.190 |
Why?
|
| Immunosorbent Techniques | 1 | 2001 | 174 | 0.190 |
Why?
|
| Genomics | 3 | 2016 | 5926 | 0.190 |
Why?
|
| Pancreas | 2 | 2005 | 1699 | 0.190 |
Why?
|
| Colitis | 2 | 2023 | 1242 | 0.190 |
Why?
|
| Interleukin-6 | 8 | 2016 | 3229 | 0.190 |
Why?
|
| Erythema Chronicum Migrans | 1 | 2021 | 48 | 0.190 |
Why?
|
| Glutamate Decarboxylase | 1 | 2002 | 239 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2025 | 992 | 0.180 |
Why?
|
| Exanthema Subitum | 1 | 2000 | 4 | 0.180 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 100 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2015 | 4355 | 0.180 |
Why?
|
| Immunoassay | 3 | 2010 | 746 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 6 | 2009 | 1082 | 0.180 |
Why?
|
| Chemokine CXCL10 | 3 | 2017 | 311 | 0.180 |
Why?
|
| Lymphatic System | 1 | 2022 | 251 | 0.180 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2001 | 203 | 0.180 |
Why?
|
| Histone Deacetylases | 2 | 2022 | 717 | 0.180 |
Why?
|
| Central Nervous System Diseases | 2 | 1999 | 520 | 0.180 |
Why?
|
| Interferon Regulatory Factors | 3 | 2011 | 271 | 0.180 |
Why?
|
| Base Sequence | 19 | 2014 | 12422 | 0.170 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2024 | 390 | 0.170 |
Why?
|
| Linkage Disequilibrium | 8 | 2013 | 1997 | 0.170 |
Why?
|
| Dinoprostone | 2 | 2014 | 597 | 0.170 |
Why?
|
| Cyclophosphamide | 8 | 1998 | 2227 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4585 | 0.170 |
Why?
|
| Genetic Testing | 5 | 2012 | 3591 | 0.170 |
Why?
|
| Interleukin-1 | 4 | 1992 | 1252 | 0.170 |
Why?
|
| Tetanus Toxoid | 7 | 2004 | 188 | 0.170 |
Why?
|
| Infectious Mononucleosis | 1 | 2000 | 133 | 0.170 |
Why?
|
| Antigens, Viral | 3 | 2000 | 995 | 0.170 |
Why?
|
| Immunity, Cellular | 6 | 2011 | 1561 | 0.170 |
Why?
|
| Gene Regulatory Networks | 2 | 2022 | 1752 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 4 | 1996 | 354 | 0.170 |
Why?
|
| Calcium Signaling | 1 | 2024 | 737 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 4 | 2023 | 2040 | 0.160 |
Why?
|
| Receptors, Antigen, B-Cell | 3 | 2022 | 547 | 0.160 |
Why?
|
| Sirolimus | 4 | 2003 | 1540 | 0.160 |
Why?
|
| Administration, Oral | 14 | 1997 | 4034 | 0.160 |
Why?
|
| beta-Synuclein | 1 | 2019 | 14 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1606 | 0.160 |
Why?
|
| Proinsulin | 1 | 1999 | 135 | 0.160 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2019 | 48 | 0.160 |
Why?
|
| Kinetics | 6 | 2007 | 6330 | 0.160 |
Why?
|
| Adaptive Immunity | 2 | 2022 | 733 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 11 | 2019 | 22380 | 0.160 |
Why?
|
| Phosphorylation | 10 | 2014 | 8316 | 0.150 |
Why?
|
| Proteolipids | 4 | 1997 | 112 | 0.150 |
Why?
|
| Neuroglia | 3 | 2022 | 960 | 0.150 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 103 | 0.150 |
Why?
|
| Cricetinae | 7 | 2008 | 2423 | 0.150 |
Why?
|
| Intestinal Diseases | 1 | 2023 | 505 | 0.150 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 9118 | 0.150 |
Why?
|
| CHO Cells | 6 | 2002 | 1379 | 0.150 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 1997 | 94 | 0.150 |
Why?
|
| Aedes | 1 | 2019 | 101 | 0.150 |
Why?
|
| Immunoglobulin Variable Region | 4 | 2011 | 420 | 0.150 |
Why?
|
| Nuclear Family | 1 | 2019 | 311 | 0.150 |
Why?
|
| Young Adult | 15 | 2024 | 60066 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 3806 | 0.150 |
Why?
|
| HIV Infections | 4 | 2018 | 17569 | 0.150 |
Why?
|
| International Cooperation | 1 | 2004 | 1436 | 0.150 |
Why?
|
| Computational Biology | 3 | 2021 | 3567 | 0.140 |
Why?
|
| Lymphocyte Culture Test, Mixed | 6 | 1995 | 510 | 0.140 |
Why?
|
| Nervous System | 1 | 2001 | 544 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2010 | 551 | 0.140 |
Why?
|
| Astrocytes | 3 | 2018 | 1350 | 0.140 |
Why?
|
| Isoenzymes | 1 | 2002 | 1688 | 0.140 |
Why?
|
| Lymphocyte Count | 4 | 2001 | 794 | 0.140 |
Why?
|
| Immunoglobulins | 5 | 2011 | 855 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2006 | 2810 | 0.140 |
Why?
|
| Plasma Cells | 3 | 2023 | 599 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2024 | 1247 | 0.140 |
Why?
|
| HIV-1 | 1 | 2014 | 6963 | 0.140 |
Why?
|
| Chemokine CXCL9 | 1 | 2017 | 135 | 0.140 |
Why?
|
| Chlamydia Infections | 1 | 2000 | 365 | 0.140 |
Why?
|
| Disease Progression | 11 | 2024 | 13668 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2011 | 1743 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 18349 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 1996 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 928 | 0.130 |
Why?
|
| Disease | 1 | 2022 | 675 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2009 | 387 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2001 | 1191 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 6 | 1993 | 619 | 0.130 |
Why?
|
| Antigens, CD1 | 4 | 2005 | 434 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 343 | 0.130 |
Why?
|
| Insulin | 3 | 2010 | 6610 | 0.130 |
Why?
|
| Interleukin-1beta | 3 | 2014 | 1028 | 0.130 |
Why?
|
| Fetal Proteins | 1 | 2016 | 100 | 0.130 |
Why?
|
| Chemokines | 3 | 2023 | 963 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2019 | 2171 | 0.120 |
Why?
|
| Histocompatibility Antigens | 3 | 2006 | 479 | 0.120 |
Why?
|
| Database Management Systems | 1 | 2016 | 263 | 0.120 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2016 | 144 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2016 | 1715 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 10 | 2009 | 6082 | 0.120 |
Why?
|
| S Phase | 3 | 1996 | 424 | 0.120 |
Why?
|
| JC Virus | 1 | 2015 | 87 | 0.120 |
Why?
|
| Herpesviridae Infections | 1 | 1996 | 269 | 0.120 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 1993 | 40 | 0.120 |
Why?
|
| Genome | 1 | 2023 | 1754 | 0.120 |
Why?
|
| DNA Primers | 6 | 2003 | 2828 | 0.120 |
Why?
|
| Vaccines | 1 | 2023 | 843 | 0.120 |
Why?
|
| Apraxias | 1 | 2014 | 58 | 0.120 |
Why?
|
| Benzeneacetamides | 1 | 2014 | 36 | 0.110 |
Why?
|
| Risk Factors | 11 | 2023 | 74944 | 0.110 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2014 | 36 | 0.110 |
Why?
|
| West Nile virus | 1 | 2014 | 77 | 0.110 |
Why?
|
| Polymorphism, Genetic | 8 | 2009 | 4249 | 0.110 |
Why?
|
| Herpes Zoster | 3 | 1998 | 252 | 0.110 |
Why?
|
| Adolescent | 20 | 2024 | 89169 | 0.110 |
Why?
|
| L-Selectin | 2 | 2005 | 212 | 0.110 |
Why?
|
| Proteomics | 2 | 2024 | 3912 | 0.110 |
Why?
|
| Genes, X-Linked | 1 | 2014 | 129 | 0.110 |
Why?
|
| Chromatin | 2 | 2024 | 2981 | 0.110 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 263 | 0.110 |
Why?
|
| Antibody Specificity | 4 | 2013 | 1065 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2016 | 2401 | 0.110 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 73 | 0.110 |
Why?
|
| Herpesvirus 6, Human | 2 | 2007 | 98 | 0.110 |
Why?
|
| Solubility | 3 | 2009 | 1086 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2010 | 820 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 2 | 1998 | 159 | 0.110 |
Why?
|
| Antigens, CD1d | 3 | 2005 | 225 | 0.110 |
Why?
|
| Cell Cycle Proteins | 2 | 2010 | 3445 | 0.110 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 189 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1673 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2015 | 825 | 0.110 |
Why?
|
| Digoxin | 1 | 2014 | 246 | 0.100 |
Why?
|
| Transcription Factors | 4 | 2022 | 12171 | 0.100 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2013 | 171 | 0.100 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2014 | 303 | 0.100 |
Why?
|
| Lysosomes | 2 | 2009 | 938 | 0.100 |
Why?
|
| Methylprednisolone | 3 | 1999 | 386 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1996 | 528 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 299 | 0.100 |
Why?
|
| Granzymes | 1 | 2014 | 277 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 3 | 2019 | 4413 | 0.100 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 393 | 0.100 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2012 | 45 | 0.100 |
Why?
|
| X Chromosome Inactivation | 1 | 2014 | 229 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2009 | 617 | 0.100 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2014 | 272 | 0.100 |
Why?
|
| Bacterial Vaccines | 3 | 2005 | 400 | 0.100 |
Why?
|
| Recombinant Proteins | 7 | 2019 | 6512 | 0.100 |
Why?
|
| Parkinson Disease | 2 | 2024 | 2893 | 0.100 |
Why?
|
| Antigens, Bacterial | 2 | 1998 | 1150 | 0.100 |
Why?
|
| HLA-D Antigens | 5 | 2008 | 130 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1999 | 1965 | 0.100 |
Why?
|
| Immunoglobulin M | 3 | 2021 | 1528 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2015 | 1524 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2013 | 892 | 0.090 |
Why?
|
| Genome, Human | 10 | 2011 | 4446 | 0.090 |
Why?
|
| Encephalomyelitis | 2 | 1991 | 37 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 615 | 0.090 |
Why?
|
| G2 Phase | 1 | 1991 | 135 | 0.090 |
Why?
|
| Neutrophils | 1 | 2024 | 3786 | 0.090 |
Why?
|
| Meningoencephalitis | 2 | 1989 | 82 | 0.090 |
Why?
|
| RNA Interference | 3 | 2015 | 2832 | 0.090 |
Why?
|
| Genetic Markers | 6 | 2014 | 2603 | 0.090 |
Why?
|
| Lyme Disease Vaccines | 2 | 2001 | 18 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1907 | 0.090 |
Why?
|
| Europe | 5 | 2016 | 3436 | 0.090 |
Why?
|
| Oligopeptides | 1 | 1996 | 1194 | 0.090 |
Why?
|
| Protein Kinase C | 2 | 1993 | 1207 | 0.090 |
Why?
|
| RNA | 3 | 2023 | 2722 | 0.090 |
Why?
|
| Organ Specificity | 4 | 2019 | 1968 | 0.090 |
Why?
|
| Child | 15 | 2024 | 80917 | 0.090 |
Why?
|
| Acetylesterase | 1 | 2010 | 14 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 5 | 1993 | 826 | 0.090 |
Why?
|
| Interleukin-23 | 2 | 2012 | 202 | 0.090 |
Why?
|
| Ventricular Dysfunction | 1 | 2011 | 144 | 0.090 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 951 | 0.090 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2010 | 21 | 0.090 |
Why?
|
| Aged | 30 | 2024 | 171502 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 1094 | 0.090 |
Why?
|
| Fibrinogen | 1 | 2014 | 891 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 3 | 1999 | 1613 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 178 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2006 | 1609 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 4913 | 0.090 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2010 | 30 | 0.090 |
Why?
|
| Microsatellite Repeats | 4 | 2007 | 785 | 0.090 |
Why?
|
| Neuritis | 1 | 1990 | 35 | 0.090 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2010 | 99 | 0.090 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2010 | 88 | 0.090 |
Why?
|
| Antigen-Antibody Complex | 1 | 2012 | 513 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 505 | 0.090 |
Why?
|
| Nervous System Diseases | 3 | 1994 | 1662 | 0.080 |
Why?
|
| Up-Regulation | 5 | 2020 | 4149 | 0.080 |
Why?
|
| Blood Donors | 1 | 2012 | 343 | 0.080 |
Why?
|
| Speech | 1 | 2014 | 557 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 693 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2011 | 341 | 0.080 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 3 | 2001 | 381 | 0.080 |
Why?
|
| Blotting, Southern | 4 | 1997 | 775 | 0.080 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2010 | 175 | 0.080 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2011 | 437 | 0.080 |
Why?
|
| Albuterol | 1 | 2010 | 211 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2010 | 146 | 0.080 |
Why?
|
| Complement C7 | 1 | 2009 | 16 | 0.080 |
Why?
|
| Protein Transport | 1 | 2015 | 1951 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 472 | 0.080 |
Why?
|
| Cluster Analysis | 4 | 2023 | 2732 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2010 | 1667 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2004 | 606 | 0.080 |
Why?
|
| TYK2 Kinase | 1 | 2009 | 38 | 0.080 |
Why?
|
| Probiotics | 1 | 2013 | 387 | 0.080 |
Why?
|
| Odds Ratio | 8 | 2020 | 9669 | 0.080 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2009 | 19 | 0.080 |
Why?
|
| Cell Polarity | 2 | 2010 | 639 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 330 | 0.080 |
Why?
|
| Kallikreins | 1 | 2010 | 219 | 0.080 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 1999 | 32 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2013 | 1361 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2008 | 10763 | 0.080 |
Why?
|
| Virus Diseases | 2 | 2008 | 724 | 0.080 |
Why?
|
| Sequence Analysis | 1 | 2009 | 240 | 0.080 |
Why?
|
| Galectins | 2 | 2009 | 295 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2744 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 14729 | 0.080 |
Why?
|
| Desensitization, Immunologic | 1 | 1994 | 558 | 0.080 |
Why?
|
| Titrimetry | 1 | 2007 | 36 | 0.080 |
Why?
|
| Immunization | 2 | 2004 | 1219 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 1495 | 0.070 |
Why?
|
| Models, Biological | 5 | 2012 | 9497 | 0.070 |
Why?
|
| Apoptosis | 5 | 2008 | 9527 | 0.070 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 979 | 0.070 |
Why?
|
| Antibodies, Blocking | 2 | 2017 | 250 | 0.070 |
Why?
|
| Calcium | 4 | 2014 | 5792 | 0.070 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 1987 | 24 | 0.070 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 165 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2015 | 3214 | 0.070 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2007 | 24 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2459 | 0.070 |
Why?
|
| Brain Diseases | 1 | 1996 | 1554 | 0.070 |
Why?
|
| Neprilysin | 1 | 2010 | 487 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2009 | 253 | 0.070 |
Why?
|
| Artifacts | 1 | 2016 | 1926 | 0.070 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 944 | 0.070 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2007 | 44 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 781 | 0.070 |
Why?
|
| Poliovirus | 1 | 1987 | 106 | 0.070 |
Why?
|
| Lipopolysaccharides | 3 | 2014 | 2222 | 0.070 |
Why?
|
| Models, Statistical | 3 | 2021 | 5107 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2015 | 1068 | 0.070 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2007 | 58 | 0.070 |
Why?
|
| Phosphotyrosine | 1 | 2007 | 458 | 0.070 |
Why?
|
| Mutation | 5 | 2017 | 30237 | 0.070 |
Why?
|
| Thymidine | 2 | 1998 | 297 | 0.070 |
Why?
|
| HLA-DQ Antigens | 2 | 1999 | 190 | 0.070 |
Why?
|
| Radiography | 2 | 2015 | 6986 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2014 | 3056 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2007 | 370 | 0.070 |
Why?
|
| Mitosis | 1 | 1991 | 1178 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2015 | 2885 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 2009 | 610 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2016 | 2981 | 0.070 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2008 | 308 | 0.070 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2007 | 260 | 0.070 |
Why?
|
| Radioimmunoassay | 2 | 2005 | 863 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2011 | 966 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2009 | 494 | 0.060 |
Why?
|
| Hybridomas | 2 | 2004 | 444 | 0.060 |
Why?
|
| Hypergammaglobulinemia | 1 | 1986 | 71 | 0.060 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 3044 | 0.060 |
Why?
|
| Synovial Fluid | 2 | 2005 | 393 | 0.060 |
Why?
|
| Equipment Failure Analysis | 3 | 2016 | 845 | 0.060 |
Why?
|
| Algorithms | 5 | 2016 | 14164 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2008 | 1151 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2014 | 14488 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2015 | 2649 | 0.060 |
Why?
|
| Recurrence | 6 | 2023 | 8509 | 0.060 |
Why?
|
| Influenza, Human | 2 | 2014 | 1541 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 2009 | 0.060 |
Why?
|
| Binding Sites | 3 | 2003 | 6019 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1197 | 0.060 |
Why?
|
| Diet | 2 | 2014 | 8089 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2012 | 1485 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 542 | 0.060 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3604 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 1469 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2654 | 0.060 |
Why?
|
| Genetic Linkage | 3 | 2005 | 2342 | 0.060 |
Why?
|
| Interleukin-13 | 2 | 2010 | 390 | 0.060 |
Why?
|
| Cysteine | 1 | 2010 | 897 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2008 | 1169 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2009 | 1219 | 0.060 |
Why?
|
| Myeloid Cells | 2 | 2021 | 839 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2016 | 2057 | 0.060 |
Why?
|
| Neoplasms | 3 | 2022 | 22371 | 0.060 |
Why?
|
| Time Factors | 11 | 2015 | 40220 | 0.060 |
Why?
|
| Software | 3 | 2014 | 4480 | 0.060 |
Why?
|
| Lewy Bodies | 1 | 2024 | 141 | 0.060 |
Why?
|
| Drug Resistance | 3 | 2010 | 1599 | 0.060 |
Why?
|
| Treatment Failure | 4 | 2022 | 2661 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2009 | 762 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 36741 | 0.060 |
Why?
|
| HTLV-I Antibodies | 2 | 1995 | 35 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2011 | 1361 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 458 | 0.060 |
Why?
|
| Apoproteins | 2 | 1996 | 45 | 0.060 |
Why?
|
| Cyclin D | 1 | 2003 | 71 | 0.060 |
Why?
|
| RNA, Viral | 3 | 2022 | 2874 | 0.060 |
Why?
|
| Myositis | 1 | 2007 | 269 | 0.060 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 628 | 0.060 |
Why?
|
| Genetics, Medical | 1 | 2006 | 334 | 0.060 |
Why?
|
| Encephalitis | 3 | 1988 | 441 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2003 | 104 | 0.050 |
Why?
|
| Phytohemagglutinins | 3 | 1998 | 165 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 588 | 0.050 |
Why?
|
| Fluoresceins | 1 | 2003 | 235 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 300 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 3610 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 438 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2023 | 85 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2008 | 748 | 0.050 |
Why?
|
| Age Factors | 3 | 2015 | 18415 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 3390 | 0.050 |
Why?
|
| Genetic Loci | 4 | 2014 | 2629 | 0.050 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2002 | 40 | 0.050 |
Why?
|
| Remission Induction | 1 | 2009 | 2410 | 0.050 |
Why?
|
| Forecasting | 1 | 2012 | 2945 | 0.050 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2022 | 30 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 3049 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2023 | 88 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 5797 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 317 | 0.050 |
Why?
|
| Esters | 1 | 2003 | 212 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1996 | 1683 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2003 | 287 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2011 | 2191 | 0.050 |
Why?
|
| HEK293 Cells | 3 | 2019 | 4280 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 6231 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 1993 | 93 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 1995 | 1703 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 199 | 0.050 |
Why?
|
| Cell Membrane | 2 | 2009 | 3655 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1351 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2007 | 2442 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 412 | 0.050 |
Why?
|
| Child, Preschool | 9 | 2021 | 42669 | 0.050 |
Why?
|
| Transfection | 4 | 2004 | 5756 | 0.050 |
Why?
|
| Vaccination | 4 | 2023 | 3437 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2008 | 2363 | 0.050 |
Why?
|
| Receptors, CXCR3 | 1 | 2023 | 240 | 0.050 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2002 | 199 | 0.050 |
Why?
|
| Uveitis | 2 | 1997 | 398 | 0.050 |
Why?
|
| Proteome | 1 | 2012 | 1890 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1885 | 0.050 |
Why?
|
| Binomial Distribution | 1 | 2021 | 23 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2023 | 492 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 3 | 2010 | 999 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2014 | 3205 | 0.050 |
Why?
|
| Proviruses | 2 | 1994 | 320 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 687 | 0.050 |
Why?
|
| Exons | 4 | 2010 | 2394 | 0.050 |
Why?
|
| Cyclins | 1 | 2003 | 606 | 0.050 |
Why?
|
| Epistasis, Genetic | 2 | 2015 | 353 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2005 | 1751 | 0.050 |
Why?
|
| Obesity | 2 | 2014 | 13091 | 0.050 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 9561 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 564 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 2892 | 0.050 |
Why?
|
| Double-Blind Method | 6 | 2022 | 12466 | 0.050 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2000 | 70 | 0.050 |
Why?
|
| Bacteria | 2 | 2024 | 2216 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 2885 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 2050 | 0.050 |
Why?
|
| Epitope Mapping | 2 | 1999 | 301 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2000 | 53 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2024 | 623 | 0.040 |
Why?
|
| Sural Nerve | 1 | 2000 | 105 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2008 | 1966 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2010 | 2857 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 588 | 0.040 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 201 | 0.040 |
Why?
|
| Equipment Design | 3 | 2016 | 3522 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 11095 | 0.040 |
Why?
|
| Cell Movement | 3 | 2023 | 5213 | 0.040 |
Why?
|
| Theilovirus | 1 | 1999 | 11 | 0.040 |
Why?
|
| Cardiovirus Infections | 1 | 1999 | 20 | 0.040 |
Why?
|
| Biopolymers | 1 | 2000 | 183 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2001 | 2179 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 681 | 0.040 |
Why?
|
| Cycloheximide | 1 | 1999 | 341 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 4786 | 0.040 |
Why?
|
| Longitudinal Studies | 4 | 2013 | 14783 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2015 | 3803 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 2 | 2016 | 942 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 1730 | 0.040 |
Why?
|
| Logistic Models | 5 | 2011 | 13290 | 0.040 |
Why?
|
| DNA | 7 | 1999 | 7213 | 0.040 |
Why?
|
| Twins | 1 | 2000 | 341 | 0.040 |
Why?
|
| Troponin | 1 | 2022 | 535 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 1999 | 168 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1512 | 0.040 |
Why?
|
| Cohort Studies | 8 | 2021 | 41753 | 0.040 |
Why?
|
| Insect Bites and Stings | 1 | 2019 | 72 | 0.040 |
Why?
|
| United States | 5 | 2019 | 73039 | 0.040 |
Why?
|
| Endothelium | 1 | 2021 | 768 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 1981 | 405 | 0.040 |
Why?
|
| Triplets | 1 | 1998 | 42 | 0.040 |
Why?
|
| Subacute Sclerosing Panencephalitis | 2 | 1988 | 26 | 0.040 |
Why?
|
| Microfluidics | 1 | 2023 | 672 | 0.040 |
Why?
|
| Cattle | 4 | 1997 | 3819 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2024 | 773 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2004 | 5028 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 253 | 0.040 |
Why?
|
| Binding Sites, Antibody | 3 | 2005 | 340 | 0.040 |
Why?
|
| Arrestin | 1 | 1997 | 30 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 231 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2001 | 3590 | 0.040 |
Why?
|
| Sample Size | 2 | 2011 | 846 | 0.040 |
Why?
|
| Graft Survival | 1 | 2008 | 3887 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2000 | 659 | 0.040 |
Why?
|
| Coma | 1 | 1981 | 485 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1737 | 0.040 |
Why?
|
| Alkylating Agents | 1 | 1997 | 132 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 1999 | 393 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1406 | 0.030 |
Why?
|
| Conserved Sequence | 2 | 1999 | 1162 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 15949 | 0.030 |
Why?
|
| Creatinine | 1 | 2022 | 1918 | 0.030 |
Why?
|
| Polyenes | 2 | 1996 | 68 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2000 | 1080 | 0.030 |
Why?
|
| Skin | 2 | 2021 | 4505 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2011 | 26421 | 0.030 |
Why?
|
| Leukemia, T-Cell | 2 | 1993 | 102 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 1998 | 472 | 0.030 |
Why?
|
| Blood | 1 | 2018 | 599 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 1998 | 447 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1998 | 287 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 652 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 1422 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1997 | 530 | 0.030 |
Why?
|
| Reference Values | 1 | 2003 | 4939 | 0.030 |
Why?
|
| Rats | 3 | 2008 | 23782 | 0.030 |
Why?
|
| Thymoma | 1 | 1997 | 188 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2021 | 1461 | 0.030 |
Why?
|
| Enterotoxins | 2 | 1995 | 366 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 2862 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5804 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2014 | 2575 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2014 | 43 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4492 | 0.030 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 8759 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 325 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 20225 | 0.030 |
Why?
|
| Spleen | 1 | 2000 | 2296 | 0.030 |
Why?
|
| Glycosylation | 1 | 1997 | 1100 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2014 | 38 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 1995 | 914 | 0.030 |
Why?
|
| Androstenols | 1 | 2014 | 25 | 0.030 |
Why?
|
| Heat-Shock Proteins | 3 | 1995 | 797 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2000 | 716 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 274 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 2014 | 363 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2022 | 1812 | 0.030 |
Why?
|
| Saliva | 1 | 2019 | 853 | 0.030 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 1994 | 41 | 0.030 |
Why?
|
| Colombia | 1 | 1995 | 287 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2024 | 2238 | 0.030 |
Why?
|
| Rheumatic Fever | 1 | 2014 | 73 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 705 | 0.030 |
Why?
|
| Phorbol Esters | 1 | 2013 | 109 | 0.030 |
Why?
|
| Western World | 1 | 2013 | 27 | 0.030 |
Why?
|
| Jurkat Cells | 2 | 2009 | 740 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 2014 | 383 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15833 | 0.030 |
Why?
|
| Cyclosporine | 2 | 1996 | 777 | 0.030 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 98 | 0.030 |
Why?
|
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 1993 | 15 | 0.030 |
Why?
|
| Yogurt | 1 | 2013 | 71 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 474 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2006 | 2295 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2014 | 264 | 0.030 |
Why?
|
| Age of Onset | 3 | 2009 | 3346 | 0.030 |
Why?
|
| Drug Therapy, Combination | 5 | 2010 | 6316 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 472 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 199 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 3728 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2010 | 2202 | 0.030 |
Why?
|
| G-Protein-Coupled Receptor Kinase 1 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Chronic Disease | 4 | 1998 | 9384 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 714 | 0.030 |
Why?
|
| Staurosporine | 1 | 1993 | 241 | 0.030 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2012 | 44 | 0.020 |
Why?
|
| Tacrolimus | 2 | 1996 | 750 | 0.020 |
Why?
|
| Comorbidity | 3 | 2014 | 10590 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2016 | 549 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1994 | 445 | 0.020 |
Why?
|
| Virus Integration | 1 | 1994 | 307 | 0.020 |
Why?
|
| Suicide, Attempted | 1 | 1981 | 1409 | 0.020 |
Why?
|
| Alkaloids | 1 | 1993 | 192 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1994 | 1305 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 399 | 0.020 |
Why?
|
| Peptide Library | 1 | 2013 | 351 | 0.020 |
Why?
|
| Cell Death | 1 | 1997 | 1680 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 1994 | 293 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2016 | 6283 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2014 | 564 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1995 | 958 | 0.020 |
Why?
|
| Telomere | 1 | 2017 | 943 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1999 | 3956 | 0.020 |
Why?
|
| Fast Foods | 1 | 2013 | 220 | 0.020 |
Why?
|
| Lipids | 1 | 2022 | 3345 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 1994 | 671 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 577 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2010 | 8741 | 0.020 |
Why?
|
| Mitogens | 1 | 1990 | 229 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2014 | 1497 | 0.020 |
Why?
|
| Influenza A virus | 1 | 2014 | 460 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2013 | 753 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1999 | 2167 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 9617 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 59626 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2012 | 527 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 1903 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 542 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2010 | 68 | 0.020 |
Why?
|
| Arginine | 1 | 2013 | 932 | 0.020 |
Why?
|
| Cloning, Molecular | 3 | 2004 | 4168 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2010 | 168 | 0.020 |
Why?
|
| Point Mutation | 1 | 1995 | 1596 | 0.020 |
Why?
|
| Base Pairing | 1 | 2010 | 139 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2014 | 910 | 0.020 |
Why?
|
| Lymphokines | 1 | 1992 | 925 | 0.020 |
Why?
|
| Reoviridae | 2 | 1987 | 162 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1992 | 1435 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 2748 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 1993 | 348 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 994 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 3740 | 0.020 |
Why?
|
| Eosinophils | 1 | 2014 | 952 | 0.020 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2009 | 43 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2010 | 347 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2009 | 268 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1991 | 605 | 0.020 |
Why?
|
| Paramyxoviridae Infections | 1 | 2009 | 57 | 0.020 |
Why?
|
| Epigenomics | 1 | 2014 | 960 | 0.020 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2009 | 50 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 342 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2015 | 1573 | 0.020 |
Why?
|
| Biopsy | 2 | 2000 | 6792 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2013 | 751 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2009 | 253 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 4 | 1999 | 6124 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 323 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2000 | 3409 | 0.020 |
Why?
|
| Genome, Viral | 1 | 1992 | 674 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1988 | 158 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1750 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 1367 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 1810 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 488 | 0.020 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1987 | 33 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 1641 | 0.020 |
Why?
|
| Finland | 1 | 2009 | 609 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 1056 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1989 | 2173 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4834 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2009 | 482 | 0.020 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2008 | 158 | 0.020 |
Why?
|
| Gene Library | 1 | 2009 | 1064 | 0.020 |
Why?
|
| Pokeweed Mitogens | 1 | 1986 | 38 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2766 | 0.020 |
Why?
|
| Lentivirus | 1 | 2009 | 518 | 0.020 |
Why?
|
| Mumps virus | 1 | 1986 | 23 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 150 | 0.020 |
Why?
|
| C-Peptide | 1 | 2008 | 443 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 1988 | 2230 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1988 | 355 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 1987 | 313 | 0.020 |
Why?
|
| Retina | 1 | 1997 | 2662 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4861 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2009 | 428 | 0.020 |
Why?
|
| Skin Tests | 1 | 1988 | 639 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 537 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2007 | 163 | 0.020 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2006 | 86 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2010 | 707 | 0.020 |
Why?
|
| Fluoroimmunoassay | 1 | 2005 | 30 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2009 | 553 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 97 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2006 | 64 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2011 | 1179 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1986 | 213 | 0.020 |
Why?
|
| Portal Vein | 1 | 2008 | 435 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2014 | 873 | 0.020 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2005 | 40 | 0.020 |
Why?
|
| Biological Assay | 1 | 1988 | 628 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2016 | 2880 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 610 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2010 | 445 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 10397 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1993 | 1430 | 0.020 |
Why?
|
| Neurons | 1 | 2024 | 9514 | 0.020 |
Why?
|
| Collagen | 1 | 1993 | 2645 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 730 | 0.020 |
Why?
|
| Solutions | 1 | 2005 | 409 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2010 | 1327 | 0.010 |
Why?
|
| Drug Approval | 1 | 2012 | 821 | 0.010 |
Why?
|
| Autopsy | 1 | 2008 | 1011 | 0.010 |
Why?
|
| Reoviridae Infections | 1 | 1984 | 59 | 0.010 |
Why?
|
| Risk | 3 | 2006 | 9613 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 751 | 0.010 |
Why?
|
| Intestines | 1 | 2013 | 1909 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3436 | 0.010 |
Why?
|
| Family Health | 1 | 2009 | 1255 | 0.010 |
Why?
|
| Sensation | 1 | 1986 | 336 | 0.010 |
Why?
|
| Follow-Up Studies | 5 | 1999 | 39354 | 0.010 |
Why?
|
| Acute Disease | 2 | 1992 | 7243 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1998 | 1553 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 2227 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2873 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1836 | 0.010 |
Why?
|
| Paralysis | 1 | 2005 | 250 | 0.010 |
Why?
|
| Causality | 1 | 2009 | 1254 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 872 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2004 | 183 | 0.010 |
Why?
|
| Atrophy | 1 | 2008 | 1646 | 0.010 |
Why?
|
| Protein Folding | 1 | 2007 | 871 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2009 | 2357 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 4573 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10840 | 0.010 |
Why?
|
| Minnesota | 1 | 2003 | 339 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2022 | 54924 | 0.010 |
Why?
|
| Life Style | 1 | 2014 | 3932 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1627 | 0.010 |
Why?
|
| Movement Disorders | 1 | 1986 | 463 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2016 | 4428 | 0.010 |
Why?
|
| Flurazepam | 1 | 1981 | 8 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2014 | 4213 | 0.010 |
Why?
|
| Australia | 1 | 2005 | 1265 | 0.010 |
Why?
|
| Chlordiazepoxide | 1 | 1981 | 42 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 324 | 0.010 |
Why?
|
| Heterozygote | 1 | 2008 | 2798 | 0.010 |
Why?
|
| Pedigree | 1 | 2009 | 4539 | 0.010 |
Why?
|
| Paraplegia | 1 | 1981 | 161 | 0.010 |
Why?
|
| Canada | 1 | 2006 | 2130 | 0.010 |
Why?
|
| Cell Cycle | 2 | 1999 | 2934 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2011 | 2982 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 1837 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 1982 | 418 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 3782 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 2592 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2001 | 26379 | 0.010 |
Why?
|
| Spinal Puncture | 1 | 1981 | 286 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2011 | 65379 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 5789 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 13013 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 1105 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 17142 | 0.010 |
Why?
|
| Liver | 1 | 1993 | 7578 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2009 | 3841 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 367 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 1997 | 318 | 0.010 |
Why?
|
| Janus Kinase 3 | 1 | 1996 | 76 | 0.010 |
Why?
|
| Guinea Pigs | 2 | 1991 | 1309 | 0.010 |
Why?
|
| Infant | 1 | 1998 | 36535 | 0.010 |
Why?
|
| Hematoma | 1 | 1981 | 766 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1996 | 117 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1981 | 561 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1997 | 642 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 3109 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1379 | 0.010 |
Why?
|
| Superantigens | 1 | 1995 | 124 | 0.010 |
Why?
|
| Cricetulus | 1 | 1996 | 812 | 0.010 |
Why?
|
| G1 Phase | 1 | 1996 | 403 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1994 | 298 | 0.010 |
Why?
|
| Family | 1 | 2005 | 3209 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 4120 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1996 | 677 | 0.010 |
Why?
|
| Mesentery | 1 | 1994 | 202 | 0.010 |
Why?
|
| Myocardium | 1 | 2007 | 4790 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1997 | 646 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1981 | 1024 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15453 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 417 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 1159 | 0.010 |
Why?
|
| Immunity, Mucosal | 1 | 1996 | 498 | 0.010 |
Why?
|
| Methotrexate | 1 | 1997 | 1721 | 0.010 |
Why?
|
| Phylogeny | 1 | 1998 | 2843 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1991 | 491 | 0.010 |
Why?
|
| Serotonin | 1 | 1994 | 1043 | 0.010 |
Why?
|
| Boston | 1 | 2003 | 9374 | 0.010 |
Why?
|
| Seizures | 1 | 1982 | 2998 | 0.010 |
Why?
|
| Placebo Effect | 1 | 1993 | 517 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1991 | 1163 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 24318 | 0.000 |
Why?
|
| Leukopenia | 1 | 1988 | 212 | 0.000 |
Why?
|
| Prognosis | 1 | 2008 | 30009 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1996 | 6229 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1994 | 2204 | 0.000 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 2433 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2010 | 81760 | 0.000 |
Why?
|
| Research Design | 2 | 1996 | 6209 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1988 | 470 | 0.000 |
Why?
|
| Ependyma | 1 | 1984 | 57 | 0.000 |
Why?
|
| Databases, Factual | 1 | 1999 | 8080 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1987 | 1266 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 2474 | 0.000 |
Why?
|
| Placebos | 1 | 1984 | 1667 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1982 | 774 | 0.000 |
Why?
|
| Frontal Lobe | 1 | 1982 | 1426 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1981 | 4850 | 0.000 |
Why?
|